Fluvirin

January 17, 2013
Tools

Vaccine: Fluvirin
Company: Novartis
Approval Date: June 20
Protects Against: Influenza

Fluvirin, Novartis' ($NVS) influenza vaccine approved for the 2012-2013 season June 20, ranked third in a list of top-selling vaccines of 2012. Sales hit an estimated $359 million. Fluvirin is approved for use in people age 4 and older. And this year, Novartis shipped 36 million doses of its vaccine to the United States--a 25% increase over last year. The push comes as a response to high demand, addressing a widespread flu season sweeping the nation. Selling the additional doses should give Novartis' sales a boost.

For more:
Special Report: Top 10 selling flu vaccines of 2012
Nasal delivery: the future of the flu vax

Special Report: Major FDA vaccine approvals of 2012
Press Releases
  • Heart Failure Study Performed by Cleveland Clinic Shows Serial Testing with Cardiac Biomarker ST2 Predicts Outcomes of Hospitalized Patients
  • Novasep and Celladon execute MYDICAR API supply agreement
  • Building a Stronger Network in the Fight Against Cancer
  • New Data Confirming Patient Satisfaction, Safety, Efficacy and Reduction of Hospital Readmissions with ActiveCare® Mobile Compression Device Following Joint Replacement Surgery Presented at AAOS Annual Meeting
  • Presage Biosciences Appoints Brad Margus to Board of Directors
  • More Press Releases
Featured Jobs
> Need a job? Need to hire? Visit our jobs site.